Discover 1,655 paid clinical trials in Raleigh, North Carolina. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,655
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Sponsor: UNC Lineberger Comprehensive Cancer Center
Sex: All
Age: 18 - 70+
Code: NCT01137643
Recruiting
'Eat Well' Produce Prescription RCT
for
Hypertension
Location: Durham NC
Sponsor: Institute for Medical Research, Inc.
Sex: All
Age: 18+
Code: NCT07534501
Recruiting
Integrated Health Care for PTSD
for
Posttraumatic Stress Disorder (PTSD)
Location: Durham NC, Little Rock AR, Dallas TX, San Diego CA,
Sponsor: Veterans Medical Research Foundation
Sex: All
Age: 18+
Code: NCT07220681
Recruiting
Self-Injury Treatment and Recovery in Veterans
for
Self-Injurious Behavior
Location: Durham NC
Sponsor: VA Office of Research and Development
Sex: All
Age: 18+
Code: NCT05969080
Recruiting
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab
for
Acute Respiratory Distress Syndrome (ARDS), ARDS,
Location: Durham NC, Chapel Hill NC, Charleston SC,
Sponsor: PPD Development, LP
Sex: All
Age: 18+
Code: NCT06701682
Phase 2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
for
End-Stage Kidney Disease, End-Stage Renal Disease
Location: Durham NC, Pittsburgh PA, Philadelphia PA,
Sponsor: VA Office of Research and Development
Sex: All
Age: 18+
Code: NCT05931276
Phase 3, Recruiting
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
for
Childhood Medulloblastoma
Location: Chapel Hill NC, Greenville NC, Winston-Salem NC,
Sponsor: Children's Oncology Group
Sex: All
Age: 4 - 21
Code: NCT05382338
Phase 3, Recruiting
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
for
Lymphatic Malformations
Location: Chapel Hill NC, Washington D.C. DC, Pittsburgh PA,
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 0 - 70+
Code: NCT05948943
Phase 2, Phase 3, Recruiting
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
for
Recurrent Lung Non-Small Cell Carcinoma,
Location: Durham NC, Pinehurst NC, South Hill VA, Lynchburg VA,
Sponsor: SWOG Cancer Research Network
Sex: All
Age: 18+
Code: NCT06616584
Phase 2, Phase 3, Recruiting
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
for
Acute Respiratory Distress Syndrome (ARDS), ARDS,
Location: Durham NC, Chapel Hill NC, Charleston SC,
Sponsor: PPD Development, LP
Sex: All
Age: 18+
Code: NCT06703073
Phase 2, Recruiting
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
for
Acral Lentiginous Melanoma,
Location: Goldsboro NC, Clinton NC, Winston-Salem NC, Clemmons NC,
Sponsor: SWOG Cancer Research Network
Sex: All
Age: 18+
Code: NCT04511013
Phase 2, Recruiting
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
for
Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8,
Location: Durham NC, New Bern NC, Florence SC, Midlothian VA,
Sponsor: NRG Oncology
Sex: Male
Age: 18+
Code: NCT05946213
Phase 3, Recruiting
Evaluating Treatments for Suicidal Veterans With PTSD
Location: Durham NC, Minneapolis MN, San Antonio TX, Seattle WA
Sponsor: VA Office of Research and Development
Sex: All
Age: 18+
Code: NCT05974631
Recruiting
Rett Syndrome Registry
for
Rett Syndrome, Rett Syndrome, Atypical, Genetic Disease,
Location: Chapel Hill NC, Greenwood SC, Baltimore MD,
Sponsor: International Rett Syndrome Foundation
Sex: All
Age: 0 - 70+
Code: NCT05432349
Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma